RxDoctor Payments Data

Jamie Garrett, NP

Family · Cottonport, LANPI 1679050728

Payments from drug & device makers

$854in general payments, 2019–2025

Across 46 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$181
  • Novo Nordisk$138
  • AstraZeneca$104
  • GSK$89
  • Amgen$42
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$42
  • plus $257 from 12 others

What the payments were for

  • Food & beverage$854100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$854 in reported general payments places this provider in the 60th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$405
Medicare patients
25
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin141$141,588
RybelsusSemaglutide57$90,760
OzempicSemaglutide64$83,598
Trelegy ElliptaFluticasone/Umeclidin/Vilanter110$81,733
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$42,848
MounjaroTirzepatide28$38,360
EliquisApixaban33$33,454
FarxigaDapagliflozin Propanediol20$31,026
JanuviaSitagliptin Phosphate26$28,012
LinzessLinaclotide35$20,796
VraylarCariprazine Hcl12$16,986
TrulicityDulaglutide14$13,002
SymbicortBudesonide/Formoterol Fumarate36$10,308
Tresiba Flextouch U-100Insulin Degludec20$9,896
Victoza 3-PakLiraglutide12$9,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$138$174,358121 claims
Boehringer IngelheimJardiance$39$141,588141 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$104$84,18192 claims
GSKTrelegy Ellipta$89$81,733110 claims
Lilly USA, LLCMounjaro, Trulicity$21$51,36242 claims
AbbVieLinzess, Vraylar$181$37,78347 claims
PfizerEliquis$16$33,45433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,610 family providers in Louisiana.

Other family in Cottonport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →